Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | RMD | ResMed Common Stock | 89.7K | Jun 30, 2023 | Direct |
David Pendarvis is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Reporting Person no longer an executive officer effective June 30, 2023.